Get started
SAB Biotherapeutics, Inc.SAB Biotherapeutics, Inc.SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

SABS chart


Full chart

SABS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪32.39 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−6.31 USD
Net income (FY)
‪−42.19 M‬ USD
Revenue (FY)
‪2.24 M‬ USD
Shares float
‪7.49 M‬
Beta (1Y)
−0.30

Employees


Employees (FY)
57
Change (1Y)
+1 +1.79%
Revenue / Employee (1Y)
‪39.28 K‬ USD
Net income / Employee (1Y)
‪−740.24 K‬ USD

About SAB Biotherapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Samuel J. Reich
Website
sab.bio
Headquarters
Miami Beach
Founded
2014
FIGI
BBG00YHY0G24
SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company. It is engaged in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. The firm produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. SAB Biotherapeutics was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

SABS news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of SABS is 3.51 USD — it has increased by 7.34% in the past 24 hours. Watch SAB Biotherapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange SAB Biotherapeutics, Inc. stocks are traded under the ticker SABS.
SABS stock has risen by 7.67% compared to the previous week, the month change is a 25.36% rise, over the last year SAB Biotherapeutics, Inc. has showed a −63.43% decrease.
We've gathered analysts' opinions on SAB Biotherapeutics, Inc. future price: according to them, SABS price has a max estimate of 25.00 USD and a min estimate of 6.00 USD. Watch SABS chart and read a more detailed SAB Biotherapeutics, Inc. stock forecast: see what analysts think of SAB Biotherapeutics, Inc. and suggest that you do with its stocks.
SABS reached its all-time high on Oct 22, 2021 with the price of 129.00 USD, and its all-time low was 2.16 USD and was reached on Aug 14, 2024. View more price dynamics on SABS chart.
See other stocks reaching their highest and lowest prices.
SABS stock is 22.12% volatile and has beta coefficient of −0.30. Track SAB Biotherapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is SAB Biotherapeutics, Inc. there?
Today SAB Biotherapeutics, Inc. has the market capitalization of ‪32.39 M‬, it has increased by 15.61% over the last week.
Yes, you can track SAB Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
SAB Biotherapeutics, Inc. is going to release the next earnings report on Jan 2, 2025. Keep track of upcoming events with our Earnings Calendar.
SABS earnings for the last quarter are −1.12 USD per share, whereas the estimation was −1.11 USD resulting in a −1.27% surprise. The estimated earnings for the next quarter are −1.16 USD per share. See more details about SAB Biotherapeutics, Inc. earnings.
SAB Biotherapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of ‪120.00 K‬ USD. In the next quarter, revenue is expected to reach ‪120.00 K‬ USD.
SABS net income for the last quarter is ‪−10.35 M‬ USD, while the quarter before that showed ‪−7.34 M‬ USD of net income which accounts for −41.09% change. Track more SAB Biotherapeutics, Inc. financial stats to get the full picture.
No, SABS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 57.00 employees. See our rating of the largest employees — is SAB Biotherapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SAB Biotherapeutics, Inc. EBITDA is ‪−46.86 M‬ USD, and current EBITDA margin is ‪−1.53 K‬%. See more stats in SAB Biotherapeutics, Inc. financial statements.
Like other stocks, SABS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SAB Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SAB Biotherapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SAB Biotherapeutics, Inc. stock shows the neutral signal. See more of SAB Biotherapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.